Year Founded
2019
Ownership
Private
Employees
~50
Stage
Phase 2
Modalities
Protein therapeutics

Allievex General Information

Preliminary promising results from ongoing clinical trials for tralesinidase alfa in Sanfilippo syndrome type B patients using intracerebroventricular administration

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Marblehead, Massachusetts
USA

Drug Pipeline

tralesinidase alfa
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Allievex's pipeline data

Book a demo

Key Partnerships

BioMarin Pharmaceutical

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Allievex Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Allievex's complete valuation and funding history, request access »

Allievex Investors

Pappas Capital (founder)
Investor Type: Venture Capital
Holding: Minority
Novo Holdings
Investor Type: Venture Capital
Holding: Minority
planning to expand investor syndicate with Series B financing
Investor Type: Venture Capital
Holding: Minority